Annals of Clinical and Laboratory Research

  • ISSN: 2386-5180
  • Journal h-index: 19
  • Journal CiteScore: 5.42
  • Journal Impact Factor: 4.64
  • Average acceptance to publication time (5-7 days)
  • Average article processing time (30-45 days) Less than 5 volumes 30 days
    8 - 9 volumes 40 days
    10 and more volumes 45 days
+44 7460731551
Awards Nomination
Indexed In
  • Genamics JournalSeek
  • China National Knowledge Infrastructure (CNKI)
  • CiteFactor
  • Directory of Research Journal Indexing (DRJI)
  • Publons
  • Euro Pub
  • Google Scholar
  • Secret Search Engine Labs
  • Zenodo
Share This Page

Opinion - (2022) Volume 10, Issue 11

The Global Modelling Consortium for Coronavirus and Cancer

Isabelle Moses*
Department of Public Health, Erasmus MC University Medical Center, Rotterdam, Netherlands
*Correspondence: Isabelle Moses, Department of Public Health, Erasmus MC University Medical Center, Rotterdam, Netherlands, Email:

Received: 02-Oct-2022, Manuscript No. IPACLR-22-13313; Editor assigned: 04-Oct-2022, Pre QC No. IPACLR-22-13313(PQ); Reviewed: 18-Oct-2022, QC No. IPACLR-22-13313; Revised: 04-Nov-2022, Manuscript No. IPACLR-22-13313(R); Published: 11-Nov-2022, DOI: 10.36648/2386- 5180.22.10.441


The COVID-19 and Cancer Global Modeling Consortium (CCGMC) was established in May 2020 to address the global need for evidence regarding the impact of interruptions and their moderation. The CCGMC intends to organise pertinent research on COVID-19 and disease and set up illuminating demonstrating stages for malignant growth control decision-production. Three interconnected work streams have been established by the CCGMC to examine the impact of COVID-19 on the outcomes of malignant growth screening and analysis, and disease risk. The focus is on developing a framework that will allow for the distribution of regularly updated short- and long-term projections of malignant growth significant outcomes. A lot of attention is being paid to evaluating potential prioritisation and recovery strategies both during and after the serious social and wellbeing administration interruptions experienced globally.


The main working group at CCGMC seeks to assess the impact of malignant growth results through direct disease impact on death or other health outcomes in patients with malignant growth, delays in analysis following suggestive show, or interruption of malignant growth treatment administrations. Early reports suggested that patients with malignant growth had a higher risk of dying from COVID-19-related causes compared to people without the disease; lung and haematological tumours have been of particular concern, as have patients who are immunosuppressed [1]. The CCGMC are directing deliberate audits to recognise the gamble after representing all jumbling and testing issues in order to represent this in displayed results. The potential adjusting impact of COVID-19 inoculation on outcomes in malignant growth patients will also be logically merged into demonstrated inputs as assessments of the effect become available. Breaks in the established procedures for dealing with cancerous growth during the COVID-19 pandemic were taken into account in various contexts.

Utilizing current, closely aligned, and approved model stages, the second CCGMC work stream focuses on evaluating the impact of screening programme disturbances on abundance malignant growth passings. There have been widespread disturbances in big league salary countries, and a study of 20 LMICs revealed that screening activities had been suspended and symptomatic focus had been interrupted following the first round of public NPIs [2]. Even a three-month interruption in colorectal malignant growth screening, according to the CCGMC partners, would result in 324-440, 980, and 800 additional passings in the Netherlands, Australia, and Canada, respectively. However, this could be greatly mitigated if missed screens are immediately caught up after the interruption. Expanding on this work, studies are ongoing that examine a variety of screening techniques for colorectal, breast, and cervical disease, considering both traditional and cutting-edge methods of risk definition.

Last but not least, public NPI initiatives aimed at containing the pandemic may also unintentionally alter behaviours associated with disease risk. Information suggests that these effects may be variable and heterogeneous, with smoking openness decreasing in some settings, a potential increase in binge drinking, a decline in active work, and a typical increase in body weight during the main wave lockdowns [3]. The CCGMC's third working gathering is now effectively overseeing surveys of behaviours related to malignant growth risks both during and after the pandemic.

The immediate and indirect effects of the COVID-19 on short- and long-term malignant growth issues must be evaluated using generally accepted models that analyse data from studies that use delegate populations, conventional information collection techniques, and tools. COVID-19 also had an impact on population-based disease library activities, particularly in LMICs. A key to completing excellent assessments is to limit this effect [4]. To illuminate evidence-based solutions that effectively limit the impact on malignant growth health system disruptions, a thorough understanding of the impact of the COVID-19 pandemic applicable to disease prevention and control, while potentially including the employment immunisation against COVID-19 antibodies, is essential. A significant cross-cutting issue among the three CCGMC work streams is the evaluation of the impact(s) of the COVID-19 pandemic on current social disparities.


  1. Morris EJA, Goldacre R, Spata E, Mafham M, Finan PJ, et al. (2021) Impact of the COVID-19 pandemic on the detection and management of colorectal cancer in England: a population-based study. Lancet Gastroenterol Hepatol 6: 199-208.
  2. Indexed at, Google Scholar, Cross Ref

  3. Niedzwiedz CL, Green MJ, Benzeval M, Campbell D, Craig P, et al. (2021) Mental health and health behaviours before and during the initial phase of the COVID-19 lockdown: longitudinal analyses of the UK Household Longitudinal Study. J Epidemiol Community Health 75: 224-231.
  4. Indexed at, Google Scholar, Cross Ref

  5. Saini KS, Tagliamento M, Lambertini M, McNally R, Romano M, et al. (2020)Mortality in patients with cancer and coronavirus disease 2019: a systematic review and pooled analysis of 52 studies.Eur J Cancer 139: 43-50.
  6. Indexed at, Google Scholar, Cross Ref

  7. Vrdoljak E, Sullivan R, Lawler M (2020)Cancer and coronavirus disease 2019; how do we manage cancer optimally through a public health crisis?. Eur J Cancer 132: 98-99.
  8. Indexed at, Google Scholar, Cross Ref